Susquehanna International Group Adds $6M in Agios Pharmaceuticals, Inc. ($AGIO)
Key Points
- Susquehanna International Group changed its Agios Pharmaceuticals, Inc. ($AGIO) stake by 17.7% last quarter, boosting to 1,344,953 shares worth $38.63 million.
- Wall Street's consensus rating on $AGIO is Buy and an average price target of $40.25.
- $AGIO last traded around $28.72.
Susquehanna International Group increased its position in Agios Pharmaceuticals, Inc. ($AGIO) by 17.7% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,344,953 shares of Agios Pharmaceuticals, Inc. after buying 202,521 shares during the quarter. Susquehanna International Group's holdings in Agios Pharmaceuticals, Inc. were worth $38.63 million as of its most recent filing.
Agios Pharmaceuticals, Inc. ($AGIO) Stock
Agios Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.